Plus Therapeutics to Present Multi-Institutional Experience Using the CNSide™ Cerebrospinal Fluid Assay in Patients with Leptomeningeal Metastases
Plus Therapeutics, Inc. (PSTV) Q3 2024 Earnings Call Transcript [Seeking Alpha]
Plus Therapeutics, Inc. (NASDAQ: PSTV) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $8.00 price target on the stock.
Plus Therapeutics Inc (PSTV) Q3 2024 Earnings Call Highlights: Navigating Financial Challenges ... [Yahoo! Finance]
Plus Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights [Yahoo! Finance]